FDA Panel: Neuronetics' depression therapy shows "questionable" efficacy
This article was originally published in Clinica
Executive Summary
The US FDA's neurological devices advisory panel raised concerns about Neuronetics' Neurostar transcranial magnetic stimulation (TMS) system last month, when though finding that the device was safe, noted that it had not yet been proven efficacious in treating depression.